Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty (XAMOS)

Bayer

Status: Completed

Conditions: Venous Thromboembolism

Treatments: Drug: Standard care treatment for VTE prophylaxis; Drug: Rivaroxaban (Xarelto, BAY59-7939)

Study type: Observational

Funder types: Industry

Identifiers

NCT00831714

13802

XA0801 (Other Identifier)

Details and patient eligibility

About

The main goal is to provide additional information to the risk-benefit assessment of the drug.

Enrollment: 19,076 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Female and male patients who will undergo elective hip or knee arthroplasty.

Exclusion criteria

• Exclusion criteria must be read in conjunction with the local product information.

Trial design

19,076 participants in 2 patient groups

Group 1

Treatment:

Drug: Rivaroxaban (Xarelto, BAY59-7939)

Group 2

Treatment:

Drug: Standard care treatment for VTE prophylaxis